Compare Neurocrine Biosciences Inc (NBIX) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Ross Stores, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $141.66 (market cap $14.36B), while Ross Stores, Inc. trades at $222.8 (market cap $71.94B). The key difference: Ross Stores, Inc. is far larger — about 5× Neurocrine Biosciences Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Ross Stores, Inc. for 48 Days on average.
| NBIX | ROST | |
|---|---|---|
Market Cap | $14.36B | $71.94B |
Volume | 1,237,180 | 2,002,519 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $255.23 |
52-Week Low | $123.10 | $147.71 |
Typical Hold Time | 23 Days | 48 Days |
Enterprise Value | $14.37B | $72.39B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Ross Stores (ROST) trades at $225.53, up 0.59% with strong fundamental performance including three consecutive earnings beats and robust profitability metrics. The stock shows bearish technical signals despite positive analyst sentiment, with 64% buy ratings and a $274.14 consensus price target representing 22% upside potential. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents compelling investment potential with strong earnings momentum and expanding profit margins, though technical weakness and competitive pressures warrant caution. The company's value-focused strategy and operational discipline support continued growth, while elevated valuation multiples and market volatility pose near-term risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
